⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SMMT News
Summit Therapeutics Inc. Common Stock
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
businesswire.com
SMMT
Summit Therapeutics to Present at the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
SMMT
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
businesswire.com
SMMT
Summit Therapeutics to Present at Upcoming Investor Conferences
businesswire.com
SMMT
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
businesswire.com
SMMT
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
businesswire.com
SMMT
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
businesswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
prnewswire.com
SMMT